Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis

PURPOSE: Most patients with pancreatic ductal adenocarcinoma (PDAC) die within 5 years following resection plus adjuvant gemcitabine (Gem) from outgrowth of occult metastases. We hypothesized that inhibition of the KRAS pathway with the MEK inhibitor trametinib would inhibit the outgrowth of occult...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Surg Oncol
Main Authors: Newhook, Timothy E., Lindberg, James M., Adair, Sara J., Kim, Alison J., Stelow, Edward B., Rahma, Osama E., Parsons, J. Thomas, Bauer, Todd W.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637098/
https://ncbi.nlm.nih.gov/pubmed/26847682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-016-5116-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki